The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 90, Issue 2-3, 2014, Pages 61-68

  Abdolahi, Amir ^a   Georas, Steve N ^a   Thomas Brenna, J ^b   Cai, Xueya ^a   Thevenet Morrison, Kelly ^a   Phipps, Richard P ^a   Lawrence, Peter ^b   Mousa, Shaker A ^c   Block, Robert C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Department of Molecular Biology and Genetics   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Aspirin; Docosahexaenoic acid; Eicosapentaenoic acid; Lysophosphatidic acid; Lysophosphatidylcholine; Omega 3 fatty acids; Platelet function

Indexed keywords

ASPIRIN; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; OMEGA-3 FATTY ACIDS; PLATELET FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASPIRIN; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; FISH OILS; FISHES; FOOD HABITS; HUMANS; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; PLATELET AGGREGATION;

EID: 84895910742     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.12.004     Document Type: Article

References (39)

1. Aoki J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004, 15:477-489.
2. Morris A.J., Panchatcharam M., Cheng H.Y., et al. Regulation of blood and vascular cell function by bioactive lysophospholipids. J. Thromb. Haemost. 2009, 7(Suppl. 1):38-43.
3. Smyth S.S., Cheng H.Y., Miriyala S., Panchatcharam M., Morris A.J. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim. Biophys. Acta 2008, 1781:563-570.
4. Siess W., Zangl K.J., Essler M., et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6931-6936.
5. Hayashi K., Takahashi M., Nishida W., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 2001, 89:251-258.
6. Zhang C., Baker D.L., Yasuda S., et al. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 2004, 199:763-774.
7. Zhou Z., Subramanian P., Sevilmis G., et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011, 13:592-600.
8. Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002, 158:227-233.
9. Tokumura A., Majima E., Kariya Y., et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 2002, 277:39436-39442.
10. van Meeteren L.A., Ruurs P., Stortelers C., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 2006, 26:5015-5022.
11. Hausmann J., Kamtekar S., Christodoulou E., et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol. 2011, 18:198-204.
12. Nishimasu H., Okudaira S., Hama K., et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat. Struct. Mol. Biol. 2011, 18:205-212.
13. Ferry G., Tellier E., Try A., et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 2003, 278:18162-18169.
14. Schober A., Siess W. Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol. 2012, 167:465-482.
15. Lin M.E., Herr D.R., Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010, 91:130-138.
16. Khandoga A.L., Pandey D., Welsch U., Brandl R., Siess W. GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques. Cardiovasc. Res. 2011, 90:157-164.
17. Yoshida K., Nishida W., Hayashi K., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108:1746-1752.
18. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
19. Li Z.G., Yu Z.C., Wang D.Z., et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 2008, 30:366-369.
20. Block R.C., Duff R., Lawrence P., et al. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82:87-95.
21. Block R.C., Abdolahi A., Smith B., et al. Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89:9-18.
22. Executive summary: standards of medical care in diabetes - 2012. Diabetes Care 2012, 32:S4-S10. American Diabetes Association.
23. Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J. Am. Med. Assoc. 2007, 297:2018-2024.
24. Pamuklar Z., Lee J.S., Cheng H.Y., et al. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler. Thromb. Vasc. Biol. 2008, 28:555-561.
25. Barber M.N., Risis S., Yang C., et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012, 7:e41456.
26. Anonymous, Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ, 308, 1994, pp. 81-106.
27. S.M. Grundy, H.B. Brewer, Jr., J.I. Cleeman, S.C. Smith, Jr., C. Lenfant, Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Circulation, 109, 2004, pp. 433-438.
28. Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study, N. Engl. J. Med., 321, 1989, pp. 129-135.
29. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation 2007, 115:3156-3164.
30. Ohmori T., Yatomi Y., Nonaka T., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 2006, 4:1271-1278.
31. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978, 2:117-119.
32. Terano T., Hirai A., Hamazaki T., et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983, 46:321-331.
33. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 2004, 27(Suppl. 1):S72-S73.
34. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:e82-292.
35. Tokumura A., Harada K., Fukuzawa K., Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta 1986, 875:31-38.
36. Pamuklar Z., Federico L., Liu S., et al. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 2009, 284:7385-7394.
37. Tomsig J.L., Snyder A.H., Berdyshev E.V., et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009, 419:611-618.
38. Albers H.M., Dong A., van Meeteren L.A., et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7257-7262.
39. Dohi T., Miyauchi K., Ohkawa R., et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin. Chim. Acta 2012, 413:207-212.